Childhood acute myeloid leukemia (AML) harboring core binding factor (CBF)–associated
translocations are considered as a favorable cytogenetic subgroup. The 2 major subtypes of …

Objective: To analyze the clinical outcome and the prognostic factor in pediatric patients with
core binding factor-acute myeloid leukemia (CBF-AML). Methods: A total of 121 newly …

Approximately 40% of patients affected by core binding factor (CBF) acute myeloid leukemia
(AML) ultimately die from the disease. Few prognostic markers have been identified. We …

e19054 Background: Acute myeloid leukemia (AML) with alterations in core binding factor
(CBF) has a favorable prognosis. The impact of complex cytogenetics or ELN 2022 adverse …

Abstract 419 Patients with core binding factor (CBF) AML [t (8; 21) and inv (16)/t (16; 16)] are
generally excluded from transplantation in first CR because of their relatively favorable …

Patients with core binding factor acute myeloid leukemia (CBF-AML) with translocation (8;
21)(q22; q22)[t (8; 21)] and inversion of chromosome 16 (p13. 1q22), or its variant t (16; …

Objective To study the clinical features and prognosis of core binding factor acute myeloid
leukemia (CBF-AML) in children. Methods A retrospective analysis was performed from the …

Background Despite being considered as good prognostic acute myelogenous leukemia
(AML), the long-term survival rate in core binding factor (CBF) AML leaves room for …

Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML
and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic …

This multi‐institutional study retrospectively evaluated clinicopathologic and genetic
characteristics in 351 patients with core‐binding‐factor acute myeloid leukemia (CBF‐AML) …